menu
    • menu
    [{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thymmune Therapeutics \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"THY-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thymmune Therapeutics \/ Pillar VC","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ Pillar VC"}]

    Find Clinical Drug Pipeline Developments & Deals by Thymmune Therapeutics

    Menu

    Thymmune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Thymmune Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Thymmune Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $37.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health's Advanced Research Proj...

                            Details : The funding will be used to restore damaged or non-functional thymus tissue by making best-in-class human induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) to restore T cell development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 29, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $37.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Thymmune Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Thymmune Therapeutics

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THY-100

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Pillar VC

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

                            Details : The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.

                            Product Name : THY-100

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : THY-100

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Pillar VC

                            Deal Size : $7.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth